Sagimet Biosciences (SGMT) Gains from Investment Securities (2022 - 2026)
Sagimet Biosciences (SGMT) recorded quarterly Gains from Investment Securities of $721081.0 in Q1 2026, up 1602.25% quarter-over-quarter from -$48000.0 in Q4 2025, and up 490431.29% on a YoY basis from N/an in Q1 2025.
Sagimet Biosciences (SGMT) Gains from Investment Securities (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Gains from Investment Securities history runs 5 years deep, the most recent figure standing at $721081.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 490431.29% year-over-year to $721081.0; the TTM figure through Mar 2026 stood at $721081.0 (up 490431.29% YoY), while the FY2025 annual figure was $5.7 million, up 28.23% from the prior year.
- Gains from Investment Securities was $721081.0 for Q1 2026 at Sagimet Biosciences, up from -$48000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $4.3 million in Q3 2024 to a low of -$104000.0 in Q4 2023.
- Historically, Gains from Investment Securities has averaged $932267.8 across 5 years, with a median of $50073.5 in 2024.
- The sharpest annual moves came in 2023 and 2026: Gains from Investment Securities sank 300.0% in 2023, then jumped 490431.29% in 2026.
- A 5-year view of Gains from Investment Securities shows it stood at -$1000.0 in 2022, then slumped by 10300.0% to -$104000.0 in 2023, then jumped by 4256.12% to $4.3 million in 2024, then tumbled by 101.11% to -$48000.0 in 2025, then jumped by 1602.25% to $721081.0 in 2026.
- The last three Gains from Investment Securities figures came in at $721081.0 (Q1 2026), -$48000.0 (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Sagimet Biosciences | 211.96 Mn | 211.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 721,081.00 |
| Mar 31, 2026 | 721,081.00 |
| Dec 31, 2025 | -48,000.00 |
| Dec 31, 2025 | -48,000.00 |
| Sep 30, 2025 | 1.28 Mn |
| Sep 30, 2025 | 1.28 Mn |
| Jun 30, 2025 | 147.00 |
| Jun 30, 2025 | 147.00 |
| Mar 31, 2025 | 147.00 |
| Mar 31, 2025 | 147.00 |
| Sep 30, 2024 | 4.32 Mn |
| Sep 30, 2024 | 4.32 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | -104,000.00 |
| Dec 31, 2023 | -104,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Sep 30, 2023 | -4,000.00 |